Age-Related Macular Degeneration Epidemiology Analysis and Forecast to 2034
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye Institution, 2021). A meta-analysis indicated a pooled prevalence of 8.69% for any AMD in adults ages 45–85 years. However, country-specific prevalence can reach 30–40%. Beyond its high prevalence, AMD is linked to severe disability, significantly impacting the quality of life and emotional well-being of affected individuals (Augood et al., 2006; Hassell, 2006; Wong et al., 2014).
In 2024, there were 13,788,126 diagnosed incident cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 3,378,351 diagnosed incident cases, while Germany accounted for the fewest cases with 1,160,172 cases in 2024. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of AMD to 15,349,696 cases in 2034 in the 7MM at an annual growth rate (AGR) of 1.13% during the forecast period.
In 2024, there were 93,262,936 total prevalent cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 23,514,756 total prevalent cases, while Germany accounted for the fewest cases with 7,799,623 cases in 2024. GlobalData epidemiologists forecast an increase in the total prevalent cases of AMD to 103,016,570 cases in 2034 in the 7MM at an AGR of 1.05% during the forecast period.
Scope
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast of the diagnosed incident cases (newly diagnosed patients), total prevalent cases (including both diagnosed and undiagnosed), and diagnosed prevalent cases of AMD. In this analysis, AMD cases are segmented into early AMD and late AMD, with late AMD further segmented into late dry AMD and wet AMD subtypes. In this report, each segment is broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total prevalent cases and diagnosed prevalent cases of late dry AMD and wet AMD were segmented for both sexes and ages 50 years and older. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. Additionally, in cases of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
Reasons to Buy
The Age-related macular degeneration (AMD) epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global AMD market.
Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Age Related Macular Degeneration reports